Education
About Us
Working with TipRanks
Follow Us
Orexo AB (ORXOF)
OTHER OTC:ORXOF
ORXOF Stock Chart & Stats
$3.82
-$0.42(-28.00%)
At close: 4:00 PM EDT
$3.82
-$0.42(-28.00%)
Day’s Range― - ―
52-Week Range$1.08 - $4.09
Previous CloseN/A
Volume3.00K
Average Volume (3M)66.00
Market Cap
$104.88M
Enterprise Value$514.89M
Total Cash (Recent Filing)$912.40M
Total Debt (Recent Filing)$492.20M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding34,710,640
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market Cap4.91
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit-3.30
Enterprise Value/Ebitda-1.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
BARDA Funding For OX390Securing BARDA support provides non-dilutive, milestone-linked funding that materially de-risks OX390 development through H1 2027. This reduces near-term cash burden, strengthens program credibility for partners, and improves the company’s runway to advance a potential commercial rescue product.
High Gross Profit MarginAn ~86.7% gross margin indicates product-level economics that are structurally favorable for scalability. If revenue stabilizes, high gross margins allow the firm to allocate more to R&D and commercialization while absorbing SG&A, improving the pathway to sustained profitability over months.
Pipeline Progress — OX472 GLP-1Positive in vivo data for OX472 diversifies Orexo’s pipeline beyond opioid dependence, potentially opening into large GLP‑1 markets. Sustained clinical progress would materially change long-term revenue mix and partnership interest, offering a structural growth avenue if development advances to clinics.
Bears Say
Negative Equity And High LeverageA negative equity position and a -30.5% equity ratio signal a precarious capital structure and high leverage. This materially restricts financing flexibility, elevates refinancing and solvency risk, and limits strategic options to fund R&D or commercial expansion without dilutive or costly funding.
Declining Revenues And Persistent LossesOngoing revenue declines combined with persistent net losses undermine operating leverage and burn cash reserves. Without sustained revenue recovery or meaningful margin cuts, the company faces structural challenges to reach positive operating profitability and to self-fund clinical and commercial activities.
Ongoing U.S. DOJ Legal ProcessAn unresolved DOJ investigation creates durable regulatory and reputational risk that can affect U.S. commercialization, payer relationships, and partner willingness to engage. Legal exposure can lead to fines, restrictions, or prolonged distraction that materially impairs strategic execution over months to years.
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $1.08 and its highest was $4.09 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $104.88M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Apr 28, 2026 which is in 71 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Feb 05, 2026. The company reported -$0.143 earnings per share for the quarter, missing the consensus estimate of -$0.034 by -$0.109.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orexo AB have?
Orexo AB has 34,710,640 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.143 in its last earnings report, missing expectations of -$0.034. Following the earnings report the stock price went down -7.963%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant R&D progress and strategic developments, such as the BARDA partnership for OX390 and positive growth in the U.S. commercial segment. However, financial challenges remain, including negative EBITDA, revenue declines in the U.S. commercial business, and market uncertainties for OX640. Despite these challenges, strategic initiatives and partnerships indicate potential for future growth.View all ORXOF earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―